Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2025-12-16			5-day change	1st Jan Change
185,600.00 ^KRW	-1.17%		-0.80%	+2.95%

Dec. 10	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
Dec. 10	Celltrion, Inc. announces Annual dividend	CI

Highlights

Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	Dec. 15	CI
Celltrion, Inc. announces Annual dividend	Dec. 10	CI
Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	Dec. 02	CI
Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	Nov. 27	CI
Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)	Nov. 26	CI
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg	Nov. 18	CI
Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab	Nov. 18	CI
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 14	CI
Prime Medicine Q3 net loss narrows	Nov. 07	RE
U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)	Oct. 30	CI
Celltrion to sell 746 million won worth of own shares	Oct. 22	RE
Celltrion's Q3 Operating Income, Sales Rise	Oct. 20	MT
Wellscare Signs A Memorandum of Understanding with Celltrion Canada	Oct. 20	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on September 17, 2025.	Oct. 17	CI
FDA Approves Expanded Pediatric Indications for YUFLYMA®? (Adalimumab-Aaty) and Unbranded Adalimumab-AatY in the United States	Oct. 17	CI
Celltrion, Inc.'s Equity Buyback announced on September 17, 2025, has closed with 572,932 shares, representing 0.26% for KRW 100,000.03 million.	Oct. 14	CI
Celltrion Receives U.S. FDA Approval for EYDENZELT®? (aflibercept-boav), Biosimilar Confirming EYLEA®? (aflibercept)	Oct. 09	CI
Celltrion, Inc. Presents Positive Real-World Data on Switching from Intravenous (Iv) to Subcutaneous (Sc) Injectioniximab At Ueg Week 2025 Meet the Expert Sessions	Oct. 06	CI
Hikma, Celltrion Sign Exclusive License Deals for Six Biosimilars in MENA Region	Oct. 06	MT
Celltrion, Inc. Launches AVTOZMA®? (Tocilizumab-anoh) Intravenous (IV) Formulation in the United States	Oct. 02	CI
Eli Lilly Reportedly Sells Imclone Systems to Celltrion for $330 Million	Sep. 24	MT
Eli Lilly Reportedly Sells Imclone Systems to Celltrion for $330 Million	Sep. 23	MT
Celltrion to Buy Eli Lilly's New Jersey Manufacturing Plant to Limit US Tariff Impact	Sep. 23	MT
South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility	Sep. 22	DJ
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows	Sep. 22	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Highlights

Filters